Valuation : Bould Opportunities PLC

Market Cap 5.71K 4.93K 4.62K 4.22K 7.93K 544K 7.97K 54.74K 21.37K 275K 21.43K 20.96K 913K P/E 2019
-0.01x
P/E 2020 -0.02x
Enterprise Value -78.29K -67.59K -63.36K -57.85K -109K -7.47M -109K -751K -293K -3.78M -294K -288K -12.53M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
76.48%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Director of Finance/CFO 65 2021-05-13
Chief Tech/Sci/R&D Officer 61 2025-01-01
Director TitleAgeSince
Director/Board Member 45 2019-01-28
Chairman 70 2019-05-20
Director/Board Member 61 2021-05-13
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+24.32% - - 3.54M
-1.93%-2.31%+1.74%+109.70% 9.97B
-5.50%-7.05%+208.63%+273.38% 2.39B
+0.06%+1.31%-31.61%-40.15% 2.13B
-1.04%-0.37%-12.22%-13.94% 1.79B
+2.64%+12.83%+93.36%+62.37% 984M
+0.41%-0.20%-28.45%-7.68% 980M
-1.85%+11.03%+79.92% - 743M
-7.42%+1.84%+5.88%+115.54% 704M
-2.28%-3.10%-14.08%+23.81% 702M
Average -1.69%+3.73%+33.69%+65.38% 2.04B
Weighted average by Cap. -1.93%-0.67%+26.72%+91.04%

Financials

2019 2020
Net sales - -
Net income -832K -718K -673K -615K -1.16M -79.36M -1.16M -7.98M -3.12M -40.13M -3.12M -3.06M -133M -306K -264K -248K -226K -425K -29.19M -427K -2.94M -1.15M -14.76M -1.15M -1.12M -48.97M
Net Debt -378K -326K -306K -279K -525K -36.05M -528K -3.63M -1.42M -18.23M -1.42M -1.39M -60.49M -84K -72.52K -67.98K -62.07K -117K -8.01M -117K -806K -315K -4.05M -315K -308K -13.44M
Logo Bould Opportunities PLC
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Employees
-